Loading...
Market
Will KarXT (Cobenfy) become the leading schizophrenia treatment in the U.S. by prescription volume by September 26, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Market analysis reports from reputable sources such as IQVIA or Symphony Health
Story
FDA Approves Bristol Myers Squibb's New Schizophrenia Drug KarXT, Brand Name Cobenfy
Sep 26, 2024, 10:44 PM
The U.S. Food and Drug Administration (FDA) has approved KarXT, a new schizophrenia drug developed by Bristol Myers Squibb, on Thursday. This marks the first new type of treatment for schizophrenia in decades and offers a significant advancement in the management of the mental disorder. KarXT, also known by its brand name Cobenfy, is notable for its effectiveness and milder side effects compared to existing treatments. The drug, approved for oral use, is a major milestone for patients and the pharmaceutical industry, as it brings renewed focus to neuropsychiatric treatments.
View original story
Similar markets
Yes • 50%
No • 50%
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%